Higher Dose Imatinib for Children With De Novo Chronic Phase Chronic Myelogenous Leukemia: A Report From the Children's Oncology Group

Pediatric Blood and Cancer - United States
doi 10.1002/pbc.23031
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Suboptimal Responses to Imatinib in Chronic Myelogenous Leukemia

Clinical Journal of Oncology Nursing
Oncology
2009English

Characteristics of Dasatinib- And Imatinib-Resistant Chronic Myelogenous Leukemia Cells

Clinical Cancer Research
Cancer ResearchOncology
2008English

Increased Cortical Bone Mineralization in Imatinib Treated Patients With Chronic Myelogenous Leukemia

Haematologica
Hematology
2008English

Chronic Myelogenous Leukemia

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2012English

Oral Effects and Early Implant Survival Results After Imatinib Discontinuation Therapy for Chronic Myelogenous Leukemia: A Case Report

Clinical advances in periodontics
Periodontics
2017English

Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia

Cancer Research
Cancer ResearchOncology
2004English

P53 in Chronic Myelogenous Leukemia in Acute Phase.

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
1991English

An Analysis of Strategic Treatment Interruptions During Imatinib Treatment of Chronic Myelogenous Leukemia With Imatinib-Resistant Mutations

Mathematical Biosciences
StatisticsGeneticsProbabilityMolecular BiologyBiochemistryApplied MathematicsMicrobiology SimulationImmunologyBiological SciencesMedicineAgriculturalModeling
2015English

Predictors and Short-Term Outcomes of Hyperleukocytosis in Children With Acute Myeloid Leukemia: A Report From the Children's Oncology Group

Haematologica
Hematology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy